Gleevec equivalent launched
New Jersey | 04 February 2016

Sun Pharma has launched its therapeutics equivalent to the cancer drug Gleevec in the US.

The announcement follows a settlement with Novartis in May 2014 that allowed Sun Pharma to launch a generic version of Gleevec this month.

The US Food and Drug Administration (FDA) approved Sun Pharma’s application for Imatinib Mesylate tablets in December 2015.

The company also secured 180 days of exclusivity from the FDA, as a first-to-file applicant.

Novartis famously lost a patent for Glivec, as it is marketed in India, in 2013, after the Supreme Court found it in violation of Section 3(d) of the Patent Act, which does not allow evergreening of drug patents with a minor tweaking of the formula.

Author: Tammy Facey



More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences
IPPRO ARCHIVES
BACK ISSUES ONLINE
COMPANY INFO
ABOUT US

THE TEAM


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization